
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is seen as a promising company with a unique approach to treating chronic inflammatory diseases through the use of obefazimod, a novel drug candidate that targets the body's natural regulatory mechanisms. Their Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis have shown positive results with high efficacy rates and limited side effects. With plans for combination development and potential interest from large pharmaceutical companies, Abivax has the potential for significant growth in a growing market, making it a solid investment opportunity.
Bears say
Abivax is facing intense competition from biosimilars, new targets, and combination therapies while only receiving limited short interest for its shares. Furthermore, the market growth rate is rapid and appears to be driven by environmental factors, and although the company's initial focus is on inflammatory bowel diseases with a combined value of approximately $23 billion, it has little to no experience in commercializing its products and its drug candidate, obefazimod, has shown concerning safety signals in its neurologic adverse events.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares